Proto-Oncogene Proteins c-mdm2

• 

  Subject Areas on Research

  • A Switch in p53 Dynamics Marks Cells That Escape from DSB-Induced Cell Cycle Arrest. 
  • A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53. 
  • A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a Chinese population. 
  • A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1. 
  • ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. 
  • Accelerated decline in lung function in cigarette smokers is associated with TP53/HDM2 polymorphisms. 
  • Aerobic glycolysis suppresses p53 activity to provide selective protection from apoptosis upon loss of growth signals or inhibition of BCR-Abl. 
  • An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction. 
  • An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis. 
  • Beta-arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression. 
  • Beta-arrestin-dependent signaling and trafficking of 7-transmembrane receptors is reciprocally regulated by the deubiquitinase USP33 and the E3 ligase Mdm2. 
  • Caspase-2-mediated cleavage of Mdm2 creates a p53-induced positive feedback loop. 
  • Cell cycle deregulation and xeroderma pigmentosum group C cell transformation. 
  • Combined p53-related genetic variants together with HPV infection increase oral cancer risk. 
  • Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. 
  • DNA damage induces phosphorylation of the amino terminus of p53. 
  • Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. 
  • Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck. 
  • Fluorine-18 Labeling of the MDM2 Inhibitor RG7388 for PET Imaging: Chemistry and Preliminary Evaluation. 
  • Genetic Variants of the MDM2 Gene Are Predictive of Treatment-Related Toxicities and Overall Survival in Patients With Advanced NSCLC. 
  • Genetic variants in p53-related genes confer susceptibility to second primary malignancy in patients with index squamous cell carcinoma of head and neck. 
  • Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. 
  • Genetic variation in MDM2 and p14ARF and susceptibility to salivary gland carcinoma. 
  • Growth factor modulation of p53-mediated growth arrest versus apoptosis. 
  • Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells. 
  • Human papillomavirus seropositivity synergizes with MDM2 variants to increase the risk of oral squamous cell carcinoma. 
  • Inhibiting effect of murine double minute-2 oncogene on apoptosis induced by retroviral-mediated wild-type p53. 
  • Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma. 
  • Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program. 
  • Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. 
  • Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. 
  • Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. 
  • LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. 
  • MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21. 
  • MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. 
  • MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. 
  • MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. 
  • MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival. 
  • Mdm2 regulates cardiac contractility by inhibiting GRK2-mediated desensitization of β-adrenergic receptor signaling. 
  • Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. 
  • Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. 
  • Modifying effect of mouse double minute-2 promoter variants on risk of recurrence for patients with squamous cell carcinoma of oropharynx. 
  • Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. 
  • Nedd4 mediates agonist-dependent ubiquitination, lysosomal targeting, and degradation of the beta2-adrenergic receptor. 
  • Overexpression of SKI oncoprotein leads to p53 degradation through regulation of MDM2 protein sumoylation. 
  • PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. 
  • Parc-ing p53 in the cytoplasm. 
  • Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. 
  • Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. 
  • Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. 
  • Prostate-specific expression of p53(R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival. 
  • RGS-GAIP-interacting protein controls breast cancer progression. 
  • Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. 
  • Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. 
  • Significance of MDM2 and P14 ARF polymorphisms in susceptibility to differentiated thyroid carcinoma. 
  • Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappaB. 
  • Stapled peptides as scaffolds for developing radiotracers for intracellular targets: Preliminary evaluation of a radioiodinated MDM2-binding stapled peptide in the SJSA-1 osteosarcoma model. 
  • TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist. 
  • The oncogenic properties of EWS/WT1 of desmoplastic small round cell tumors are unmasked by loss of p53 in murine embryonic fibroblasts. 
  • Validating the meta-analytical results on MDM2, CASP8, XRCC3 polymorphisms and breast cancer risk: examination of Hardy-Weinberg Equilibrium. 
  • [Murine Doube Minute 2 oncogene inhibited apoptosis induced by retroviral-mediated wild-type p53]. 
  • [Studies on MDM2 oncogene expression and its effect on pancreatic carcinoma cells]. 
  • beta-arrestin-1 competitively inhibits insulin-induced ubiquitination and degradation of insulin receptor substrate 1. 
  • p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. 
  • p53 and MDM2 immunostaining in pulmonary blastomas and bronchogenic carcinomas. 
  • p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors. 
  • {beta}-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase.